|Bid||203.98 x 800|
|Ask||221.41 x 900|
|Day's range||207.31 - 213.44|
|52-week range||181.36 - 449.34|
|Beta (5Y monthly)||1.34|
|PE ratio (TTM)||23.89|
|Earnings date||01 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||273.50|
Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.
Charles River's (CRL) manufacturing collaboration with Cure AP-4 will support the latter's Phase I/II gene therapy trials for a rare neurodegenerative disorder.
WILMINGTON, Mass., September 08, 2022--Charles River Laboratories to Present at September Conferences